Evidence map›Paper›PMID 20227509›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2010

NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.

Mitchell S Cairo, Craig T Jordan, Carlo C Maley, Clifford Chao, Ari Melnick, Scott A Armstrong, Warren Shlomchik, Jeff Molldrem, Soldano Ferrone, Crystal Mackall and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  2. Review
  3. Article
  4. Article
  5. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017
    Article
  6. Review
  7. Article
  8. Review
  9. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Article
  10. Review
  11. Article
  12. Article
  13. Minimal residual disease following allogeneic hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

Mitchell S CairoDepartment of Pediatrics, Medicine, and Pathology, Columbia University, Morgan Stanley Children's Hospital, New York-Presbyterian Hospital, New York, New York 10032, USA. mc1310@columbia.edu
Craig T Jordan
Carlo C Maley
Clifford Chao
Ari Melnick
Scott A Armstrong
Warren Shlomchik
Jeff Molldrem
Soldano Ferrone
Crystal Mackall
Laurence Zitvogel
Michael R Bishop
Sergio A Giralt
Carl H June
Columbia University · USHarvard University · USInstitut Gustave Roussy · FRNewYork–Presbyterian Hospital · USThe University of Texas MD Anderson Cancer Center · USThe Wistar Institute · USUniversity of Pennsylvania · USUniversity of Rochester Medical Center · USUPMC Hillman Cancer Center · USYale University · USYeshiva University · US

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Immunobiology of Pediatric TumorsZIABC011073 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MACKALL, CRYSTAL · 2009 to 2015
$8.4M
Tissue Procurement / ImmunohistologyP01CA109688 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCHLESSELMAN, JAMES J · 2006 to 2010
$5.9M
Developing Immune Based TherapiesZIABC011072 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MACKALL, CRYSTAL · 2009 to 2010
$2.6M
Combinatorial targeting of melanoma initiating cellsR01CA138188 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRONE, SOLDANO · 2008 to 2012
$1.5M
Antigen processing and HLA-peptide complexes in head and neck cancerR01CA110249 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRONE, SOLDANO · 2006 to 2010
$1.5M
Relapse after Allogeneic Hematopoietic Stem Cell TransplantationZIABC011239 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BISHOP, MICHAEL R · 2009 to 2011
$544k
NCI NIH HHS P01 CA109688NCI NIH HHS R01 CA110249NCI NIH HHS R01 CA138188NCI NIH HHS U10 CA098543
6 · The paper itself

Abstract

Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.

Indexed as

Graft vs Tumor EffectHematopoietic Stem Cell TransplantationBiomedical ResearchDrug Resistance, NeoplasmEpigenesis, GeneticGene Expression Regulation, NeoplasticHematologic NeoplasmsHumansNeoplastic Stem CellsRadiation ToleranceSecondary PreventionTransplantation, Homologous

Identifiers

PMID20227509
PMCPMC3711411
OpenAlexW2096283150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.